Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Anne-Laure RenaultNoura MebiroukLaetitia FuhrmannGuillaume BataillonEve CavaciutiDorothée Le GalElodie GirardTatiana PopovaPhilippe La RosaJuana BeauvalletSéverine Eon-MarchaisMarie-Gabrielle DondonCatherine Dubois d'EnghienAnthony LaugéWalid ChemlaliVirginie RaynalMartine LabbéIvan BiècheSylvain BaulandeJacques-Olivier BayPascaline BerthetOlivier CaronBruno BuecherLaurence FaivreMarc FresnayMarion Gauthier-VillarsPaul GestaNicolas JaninSophie LejeuneChristine MaugardSébastien MouttonLaurence Venat-BouvetHélène ZattaraJean-Pierre FrickerLaurence GladieffIsabelle Coupiernull nullnull nullnull nullGeorgia Chenevix-TrenchJanet HallAnne Vincent-SalomonDominique Stoppa-LyonnetNadine AndrieuFabienne LesueurPublished in: Breast cancer research : BCR (2018)
Although ATM is involved in the DNA damage response, ATM-associated tumours are distinct from BRCA1-associated tumours in terms of morphological characteristics and genomic alterations, and they are also distinguishable from sporadic breast tumours, thus opening up the possibility to identify ATM variant carriers outside the ataxia-telangiectasia disorder and direct them towards effective cancer risk management and therapeutic strategies.